Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Burkitt Lymphoma
Drug:
Rituxan (rituximab)
(
CD20 inhibitor
)
Regimen:
CODOX-M (cyclophosphamide + cytarabine + doxorubicin hydrochloride + + vincristine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
AIDS-related B-cell lymphomas: treatment…burkitt lymphoma…suggested regimens…preferred regimens…CODOX-M/IVAC (modified): cyclophosphamide, vincristine, doxorubicine, high-dose methotrexate alternating with ifosfamide, etoposide, high-dose cytrabine + rituximab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login